Although Rheumatologists Indicate There is an Unmet Need for New RA Drug Therapies, Most Patients Do Not Want to Switch from Their Current Medication, According to a New Report from BioTrends Research Group
May 29, 2013 - Exton, Penn.
– BioTrends Research Group, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that rheumatoid arthritis patients are moderately to highly satisfied with the drugs, biologic and non-biologic, they are currently taking for their condition. Most of the surveyed patients indicate they are unlikely to request a change in therapy in the next year, supporting the finding that they are satisfied with their current medication.
The PatientTrends® Rheumatoid Arthritis (US) 2013
report finds that conventional disease-modifying antirheumatic drugs (DMARDs) are rated highest on ease of use and cost due to their oral formulations and generic availability. However, despite the fact that Pfizer’s Xeljanz is a new oral agent, rheumatoid arthritis patients express a low likelihood to ask their doctor to prescribe Xeljanz, post-exposure to Xeljanz’s profile. The high patient drug satisfaction finding is contrary to rheumatologists’ views of the currently available rheumatoid arthritis drug treatments where, in the TreatmentTrends® Rheumatoid Arthritis (US) 2012
report, close to 50 percent of surveyed rheumatologists rated rheumatoid arthritis as a disease with a high unmet need for new drug therapies.
“Approximately half of the surveyed rheumatoid arthritis patients taking conventional DMARDs and/or biologics do not experience any side effects,” said BioTrends Senior Data Analyst Jen Dolga. “Therefore, if their current drug is working and they are not experiencing side effects, the patients are not going to ask their doctors to change their medication.”